Gene info: ID 64127

Gene: NOD2

GENE ID: 64127

Description: nucleotide binding oligomerization domain containing 2

Gene type: protein-coding

Location: 16q12.1

dbXrefs: Ensembl:ENSG00000167207 MIM:605956 Vega:OTTHUMG00000133171 UniprotKB:Q9HC29

RefSeq: NG_007508.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 51

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 8.531e-1 (AD) 5.550e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RHOH	0.867
FAM3B	0.861
SNX20	0.859
IL4I1	0.859
TFEC	0.858
LRRC25	0.857
TLR1	0.848
NCF1	0.848
CASP5	0.839
DAPP1	0.838

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
KCNIP3	-0.425
MYADML2	-0.424
NEUROD6	-0.418
SCRT1	-0.418
CHRNA4	-0.411
WFDC1	-0.411
FNDC5	-0.409
TM7SF2	-0.408
HRH3	-0.403
EXTL1	-0.403

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB13615	Mifamurtide	Small Molecule	838853-48-8	Approved\|Experimental	Target

ID	Drug Name	Action	PubMed
C046760	15-acetyldeoxynivalenol	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [15-acetyldeoxynivalenol results in increased expression of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	Acetylmuramyl-Alanyl-Isoglutamine binds to and affects the activity of NOD2 protein	18413660
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [15-acetyldeoxynivalenol results in increased expression of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL8 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of ATF3 mRNA	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which results in increased stability of ATF3 mRNA	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [NOD2 protein binds to NOD2 protein]	18413660
D000119	Acetylmuramyl-Alanyl-Isoglutamine	ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [NOD2 protein binds to NOD2 protein]]	18413660
D000119	Acetylmuramyl-Alanyl-Isoglutamine	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA]	22003189
D000119	Acetylmuramyl-Alanyl-Isoglutamine	Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein	16299289\|2200318
D000841	Anisomycin	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]	22003189
D000841	Anisomycin	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]	22003189
D000841	Anisomycin	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL8 mRNA]	22003189
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of NOD2 mRNA	24449571
D001151	Arsenic	Arsenic affects the expression of NOD2 mRNA	28793237
D001151	Arsenic	[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of NOD2 mRNA	28793237
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of NOD2 mRNA	23735875
C006780	bisphenol A	bisphenol A results in decreased expression of NOD2 mRNA	26364221
C006780	bisphenol A	bisphenol A results in decreased expression of NOD2 mRNA	25181051
C018475	butyraldehyde	butyraldehyde results in increased expression of NOD2 mRNA	26079696
D002101	Cacodylic Acid	[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of NOD2 mRNA	28793237
D002939	Ciprofloxacin	NOD2 gene SNP results in decreased susceptibility to Ciprofloxacin	18371140
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of NOD2 mRNA	19549813
D003474	Curcumin	Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [NOD2 protein binds to NOD2 protein]]	18413660
D003474	Curcumin	Curcumin inhibits the reaction [lauric acid promotes the reaction [NOD2 protein binds to NOD2 protein]]	18413660
D016572	Cyclosporine	Cyclosporine results in increased expression of NOD2 mRNA	27989131
C007262	deoxynivalenol	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of ATF3 mRNA]	22003189
C007262	deoxynivalenol	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]	22003189
C007262	deoxynivalenol	[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]	22003189
C007262	deoxynivalenol	[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of ATF3 mRNA	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA	22003189
C007262	deoxynivalenol	[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA	22003189
C007262	deoxynivalenol	ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein]	22003189
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]	22003189
C007262	deoxynivalenol	ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA]	22003189
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of NOD2 mRNA]	27941970
D004041	Dietary Fats	[AGT protein affects the susceptibility to Dietary Fats] which affects the expression of NOD2 mRNA	26704350
D002117	Calcitriol	Calcitriol results in increased expression of NOD2 mRNA	16002434
C118739	entinostat	entinostat results in increased expression of NOD2 mRNA	27188386
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of NOD2 mRNA	26752646
C030358	lauric acid	Curcumin inhibits the reaction [lauric acid promotes the reaction [NOD2 protein binds to NOD2 protein]]	18413660
C030358	lauric acid	lauric acid promotes the reaction [NOD2 protein binds to NOD2 protein]	18413660
C008261	lead acetate	lead acetate results in increased expression of NOD2 mRNA	20542052
D008070	Lipopolysaccharides	[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOD2 mRNA	21878375
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of NOD2 mRNA	25890327
D008070	Lipopolysaccharides	[TNF protein co-treated with IL1B protein co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOD2 mRNA	20816778
D008727	Methotrexate	Methotrexate results in decreased expression of NOD2 mRNA	17400583
C500085	muraglitazar	muraglitazar results in decreased expression of NOD2 mRNA	21515302
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of NOD2 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of NOD2 mRNA"	25554681
D009532	Nickel	Nickel results in increased expression of NOD2 mRNA	25583101
C089730	rosiglitazone	rosiglitazone results in decreased expression of NOD2 mRNA	21515302
D012834	Silver	Silver results in increased expression of NOD2 mRNA	26014281
D053260	Soot	Soot results in increased expression of NOD2 mRNA	26551751
C501413	tesaglitazar	tesaglitazar results in decreased expression of NOD2 mRNA	21515302
D014241	Trichloroethylene	Trichloroethylene results in increased methylation of NOD2 gene	27618143
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in increased expression of NOD2 mRNA	22147983
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in increased expression of NOD2 protein	22147983
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in increased expression of NOD2 mRNA	16891783
C057693	troglitazone	troglitazone results in decreased expression of NOD2 mRNA	21515302

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003779	actin binding	-	IDA	24790089
GO:0005515	protein binding	-	IPI	11087742 11472070 15107016 15753091 16203728 16714539 17337451 18511561 19337385 20534456 21699783 22684479 22700971 22829933 23376921 23711367 24695226 28436939
GO:0005524	ATP binding	-	IEA	-
GO:0019899	enzyme binding	-	IPI	15753091
GO:0019901	protein kinase binding	-	IPI	15075345 24790089 25891078
GO:0030544	Hsp70 protein binding	-	IPI	24790089
GO:0032500	muramyl dipeptide binding	-	IDA	15998797
GO:0042834	peptidoglycan binding	-	IDA	15998797
GO:0050700	CARD domain binding	-	IPI	11087742
GO:0051879	Hsp90 protein binding	-	IDA	24790089

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000187	activation of MAPK activity	-	TAS	-
GO:0002367	cytokine production involved in immune response	-	IMP	16260731
GO:0002374	cytokine secretion involved in immune response	-	IMP	20441518
GO:0002606	positive regulation of dendritic cell antigen processing and presentation	-	ISS	-
GO:0002732	positive regulation of dendritic cell cytokine production	-	IEA	-
GO:0002830	positive regulation of type 2 immune response	-	IMP	21172192
GO:0006952	defense response	-	TAS	15967716
GO:0007254	JNK cascade	-	TAS	-
GO:0007584	response to nutrient	-	IEA	-
GO:0009595	detection of biotic stimulus	-	TAS	15967716
GO:0016045	detection of bacterium	-	IDA	15653568
GO:0023052	signaling	-	IBA	21873635
GO:0030277	maintenance of gastrointestinal epithelium	-	IMP	17058067
GO:0032495	response to muramyl dipeptide	-	IBA	21873635
GO:0032495	response to muramyl dipeptide	-	IDA	15998797 16414084
GO:0032495	response to muramyl dipeptide	-	IMP	24790089
GO:0032498	detection of muramyl dipeptide	-	IDA	12527755 15998797
GO:0032731	positive regulation of interleukin-1 beta production	-	IMP	21040358
GO:0032733	positive regulation of interleukin-10 production	-	ISS	-
GO:0032740	positive regulation of interleukin-17 production	-	IMP	17919942
GO:0032755	positive regulation of interleukin-6 production	-	IDA	16414084
GO:0032757	positive regulation of interleukin-8 production	-	IMP	24790089
GO:0032760	positive regulation of tumor necrosis factor production	-	IDA	17187069
GO:0032760	positive regulation of tumor necrosis factor production	-	IMP	21040358
GO:0032874	positive regulation of stress-activated MAPK cascade	-	IDA	17187069
GO:0035556	intracellular signal transduction	-	IBA	21873635
GO:0035556	intracellular signal transduction	-	IDA	15653568
GO:0042742	defense response to bacterium	-	IBA	21873635
GO:0042742	defense response to bacterium	-	IDA	15653568
GO:0043123	positive regulation of I-kappaB kinase/NF-kappaB signaling	-	IBA	21873635
GO:0043123	positive regulation of I-kappaB kinase/NF-kappaB signaling	-	IDA	11087742 12527755
GO:0043406	positive regulation of MAP kinase activity	-	ISS	-
GO:0043552	positive regulation of phosphatidylinositol 3-kinase activity	-	ISS	-
GO:0045087	innate immune response	-	IDA	23806334
GO:0045087	innate immune response	-	NAS	17690884
GO:0045747	positive regulation of Notch signaling pathway	-	ISS	-
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IDA	21887730
GO:0046330	positive regulation of JNK cascade	-	IDA	17187069
GO:0046645	positive regulation of gamma-delta T cell activation	-	ISS	-
GO:0050679	positive regulation of epithelial cell proliferation	-	ISS	-
GO:0050718	positive regulation of interleukin-1 beta secretion	-	IDA	15107016
GO:0050727	regulation of inflammatory response	-	IC	11385577
GO:0050871	positive regulation of B cell activation	-	IDA	20844241
GO:0051092	positive regulation of NF-kappaB transcription factor activity	-	IDA	11385577 12527755 21887730
GO:0051092	positive regulation of NF-kappaB transcription factor activity	-	IMP	16203728 24790089
GO:0051092	positive regulation of NF-kappaB transcription factor activity	-	TAS	-
GO:0051259	protein complex oligomerization	-	TAS	15967716
GO:0051353	positive regulation of oxidoreductase activity	-	ISS	-
GO:0051770	positive regulation of nitric-oxide synthase biosynthetic process	-	ISS	-
GO:0060585	positive regulation of prostaglandin-endoperoxide synthase activity	-	ISS	-
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	ISS	-
GO:0070423	nucleotide-binding oligomerization domain containing signaling pathway	-	TAS	-
GO:0070431	nucleotide-binding oligomerization domain containing 2 signaling pathway	-	IDA	12527755 23806334
GO:0070498	interleukin-1-mediated signaling pathway	-	TAS	-
GO:0071224	cellular response to peptidoglycan	-	IEA	-
GO:0071225	cellular response to muramyl dipeptide	-	IDA	21887730
GO:0071225	cellular response to muramyl dipeptide	-	IMP	25093298
GO:0071407	cellular response to organic cyclic compound	-	IEA	-
GO:1900017	positive regulation of cytokine production involved in inflammatory response	-	IDA	24671169
GO:1901224	positive regulation of NIK/NF-kappaB signaling	-	IMP	25093298
GO:1902523	positive regulation of protein K63-linked ubiquitination	-	IMP	25891078
GO:2000110	negative regulation of macrophage apoptotic process	-	ISS	-
GO:2000363	positive regulation of prostaglandin-E synthase activity	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	COLOCALIZES_WITH	IBA	21873635
GO:0005737	cytoplasm	-	IDA	21887730 24790089 25093298
GO:0005737	cytoplasm	-	TAS	15967716
GO:0005739	mitochondrion	-	IEA	-
GO:0005794	Golgi apparatus	-	IDA	-
GO:0005829	cytosol	-	IBA	21873635
GO:0005829	cytosol	-	IDA	15998797
GO:0005829	cytosol	-	TAS	-
GO:0005856	cytoskeleton	-	IDA	21887730
GO:0005886	plasma membrane	-	IDA	15998797 25093298
GO:0008180	COP9 signalosome	colocalizes_with	IDA	17337451
GO:0009986	cell surface	-	IDA	16714539
GO:0016323	basolateral plasma membrane	-	IDA	16203728
GO:0031982	vesicle	-	IDA	15998797 21887730
GO:0032991	protein-containing complex	-	IDA	21887730

KEGG ID	KEGG Term
hsa04621	NOD-like receptor signaling pathway
hsa05131	Shigellosis

Reactome ID	Reactome Term	Evidence
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	TAS
R-HSA-166058	MyD88:Mal cascade initiated on plasma membrane	TAS
R-HSA-166166	MyD88-independent TLR4 cascade	TAS
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	TAS
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	TAS
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	TAS
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	TAS
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	TAS
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	TAS
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168249	Innate Immune System	IEA
R-HSA-168256	Immune System	TAS
R-HSA-168256	Immune System	IEA
R-HSA-168638	NOD1/2 Signaling Pathway	TAS
R-HSA-168638	NOD1/2 Signaling Pathway	IEA
R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	TAS
R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	IEA
R-HSA-168898	Toll-Like Receptors Cascades	TAS
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	TAS
R-HSA-446652	Interleukin-1 family signaling	TAS
R-HSA-448424	Interleukin-17 signaling	TAS
R-HSA-449147	Signaling by Interleukins	TAS
R-HSA-450294	MAP kinase activation	TAS
R-HSA-450302	activated TAK1 mediates p38 MAPK activation	TAS
R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	TAS
R-HSA-5688426	Deubiquitination	TAS
R-HSA-5689896	Ovarian tumor domain proteases	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-9020702	Interleukin-1 signaling	TAS
R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	TAS
R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	TAS
R-HSA-975155	MyD88 dependent cascade initiated on endosome	TAS
R-HSA-975871	MyD88 cascade initiated on plasma membrane	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
21243434	Non-Jewish Israeli IBD patients have significantly higher glutathione S-transferase GSTT1-null frequency. (2011 Jul)	Karban A	Dig Dis Sci
15367194	CARD15 gene mutations in periodontitis. (2004 Oct)	Laine ML	J Clin Periodontol
22739221	Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. (2013 Mar)	Nasir BF	J Clin Gastroenterol
28668336	The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. (2017 Jul)	Kuenzig ME	EBioMedicine
22719818	Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. (2012)	Li E	PLoS One
16497618	Clinically active Crohn's disease in the presence of a low C-reactive protein. (2006 Mar)	Florin TH	Scand J Gastroenterol
21247480	Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking. (2011 Jan 19)	Whitwell SC	BMC Public Health
28631723	Pharmacogenetic biomarkers of response in Crohn's disease. (2018 Jan)	Linares-Pineda TM	Pharmacogenomics J
15930979	The emergence of inflammatory bowel disease in the Asian Pacific region. (2005 Jul)	Ouyang Q	Curr Opin Gastroenterol
22269043	Clinical predictors of inflammatory bowel disease in a genetically well-defined Caucasian population. (2012 Jan 23)	Kanaan ZM	J Negat Results Biomed
16416181	Gastroduodenal Crohn's disease is associated with NOD2/CARD15 gene polymorphisms, particularly L1007P homozygosity. (2005 Dec)	Mardini HE	Dig Dis Sci
21206965	IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes. (2011 Mar)	Lauriola M	Int J Mol Med
24124330	Role of Salmonella enterica exposure in Chilean Crohn's disease patients. (2013 Sep 21)	Alvarez-Lobos M	World J Gastroenterol
24461721	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. (2014 Aug)	Fowler SA	J Crohns Colitis
21931826	Cigarette smoke extract (CSE) delays NOD2 expression and affects NOD2/RIPK2 interactions in intestinal epithelial cells. (2011)	Aldhous MC	PLoS One
22416979	A case-only study of gene-environment interaction between genetic susceptibility variants in NOD2 and cigarette smoking in Crohn's disease aetiology. (2012 Mar 14)	Helbig KL	BMC Med Genet
29434451	Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn's disease. (2018 Feb 7)	Gathungu G	World J Gastroenterol
15896420	Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. (2005 Jun)	Thompson-Chagoyan OC	Clin Nutr
22298958	Predictors of aggressive inflammatory bowel disease. (2011 Oct)	Yarur AJ	Gastroenterol Hepatol (N Y)
17030188	TUCAN (CARD8) genetic variants and inflammatory bowel disease. (2006 Oct)	McGovern DP	Gastroenterology
24989722	Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. (2015 Feb)	Doecke JD	J Gastroenterol Hepatol
21730793	Influence of Crohn's disease risk alleles and smoking on disease location. (2011 Aug)	Chen H	Dis Colon Rectum
12631668	Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. (2003 Apr)	Louis E	Gut
19826411	NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. (2010 Feb)	Dassopoulos T	Am J Gastroenterol
15180737	NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease. (2004 Jun)	Karban A	Am J Gastroenterol
15674107	The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. (2005 Jan)	Pierik M	Inflamm Bowel Dis
21621776	Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms. (2011 Sep)	Roberts RL	Atherosclerosis
18402167	[Epidemiology and risk factors of inflammatory bowel diseases]. (2007 Jun)	Colombel JF	Bull Acad Natl Med
16052966	[Epidemiology and risk factors of inflammatory bowel diseases]. (2005 May 15)	Vernier G	Rev Prat
20195604	Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. (2010 Jul)	Cunningham MF	World J Surg
22879519	The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. (2013 Oct)	Tyler AD	Gut
28506689	Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice. (2017 Aug)	Yadav P	Gastroenterology
14555911	Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. (2003 Sep)	Brant SR	Inflamm Bowel Dis
27304445	Coexistent chronic myelogenous leukemia with squamous cell carcinoma of the larynx associated with NOD2/CARD15 mutation in a young adult. (2016 Jun)	Fraczek M	Ear Nose Throat J
19953089	Differences in genetic background between active smokers, passive smokers, and non-smokers with Crohn's disease. (2010 May)	van der Heide F	Am J Gastroenterol
19422935	Genetic risk profiling and prediction of disease course in Crohn's disease patients. (2009 Sep)	Henckaerts L	Clin Gastroenterol Hepatol
18671817	ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. (2008 Oct)	Fowler EV	Am J Gastroenterol
19716246	[Inflammatory bowel disease: genetic or environmental diseases?]. (2009 Aug-Sep)	Cortot A	Gastroenterol Clin Biol
15770725	Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. (2005 Mar 14)	Lakatos PL	World J Gastroenterol
28684279	Interaction Between NOD2 and Smoking in the Pathogenesis of Crohn's Disease. (2017 Jul)	Heerasing N	EBioMedicine
22115380	Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. (2011 Dec)	Mazor Y	J Crohns Colitis
12555995	The pathogenesis of Crohn's disease in the 21st century. (2002 Dec)	Hume G	Pathology
28826742	A comprehensive review and update on Crohn's disease. (2018 Feb)	Gajendran M	Dis Mon
16161956	[Does smoking influence the course of Crohn's disease in patients with the presence of gene NOD2/CARD15 mutation?]. (2005 May)	Dobrowolska-Zachwieja A	Pol Merkur Lekarski
16489646	Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. (2006 Jan 21)	Mendoza JL	World J Gastroenterol
19513023	Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository. (2009 Sep)	Bhat M	Am J Gastroenterol
27014752	Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease. (2016 Mar)	Hume GE	J Gastrointestin Liver Dis
22822007	Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial. (2012 Jul 20)	Hollands GJ	BMJ
15472511	Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. (2004 Sep)	Smith BR	Inflamm Bowel Dis
16491045	Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. (2002 Sep)	Fiocchi C	Minerva Gastroenterol Dietol
11875755	CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. (2002 Apr)	Lesage S	Am J Hum Genet